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NeurodegenerationPeroxisome proliferator-activated receptor γ (PPARγ) agonists have been shown to provide neuroprotec-
tion in a number of neurodegenerative diseases including Parkinson's disease and Alzheimer's disease.
These protective effects are primarily considered to result from the anti-inﬂammatory actions of PPARγ,
however, there is increasing evidence that anti-oxidant mechanisms may also contribute. This study ex-
plored the impact of the PPARγ agonist rosiglitazone and the PPARγ antagonist GW9662 in the MPP+/
MPTP (1-methyl-4-phenylpyridinium/1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model of Parkin-
son's disease, focussing on oxidative stress mechanisms. Rosiglitazone attenuated reactive oxygen species
formation induced byMPP+ in SH-SY5Y cells concurrent with an upregulation of glutathione-S-transferase
activity, but not superoxide dismutase activity. These responses were not attenuated by cotreatment with
GW9662 suggesting that PPARγ activation is not required. The localisation of PPARγ in vivo to dopaminer-
gic neurons of the substantia nigra pars compacta (SNpc) was established by immunohistochemistry and
PPARγ levels were found to be upregulated 7 days after MPTP treatment. The importance of PPARγ in pro-
tecting against MPTP toxicity was conﬁrmed by treating C57BL6 mice with GW9662. Treatment with
GW9662 increased MPTP-induced neuronal loss in the SNpc whilst not affecting MPTP-induced reductions
in striatal dopamine and 3,4-dihdroxyphenylacetic acid. GW9662 also caused neuronal loss in the SNpc of
saline-treatedmice. The evidence presented here supports the role of anti-oxidant mechanisms in the pro-
tective effects of PPARγ agonists in neurodegenerative diseases, but indicates that these effects may be in-
dependent of PPARγ activation. It also demonstrates the importance of PPARγ activity for neuronal
survival within the SNpc.
© 2012 Elsevier Inc. Open access under CC BY license.Introduction
Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand
activated transcription factor with a wide variety of biological roles
including control of lipid metabolism and regulation of inﬂammation
(Delerive et al., 2001; Desvergne and Wahli, 1999; Devchand et al.,
1996). Inﬂammation is an important feature in the pathogenesis of
a whole spectrum of neurodegenerative diseases (Glass et al., 2010),
consequentially PPARγ agonists have the potential to provide neuro-
protective effects. Protective effects have been seen with PPARγ ago-
nists in murine models of Alzheimer's disease (Escribano et al., 2009),
Parkinson's disease (PD) (Dehmer et al., 2004; Breidert et al., 2002;
Schintu et al., 2009; Carta et al., 2011), amyotrophic lateral sclerosis
(Kiaei et al., 2005), Huntington's disease (Quintanilla et al., 2008)
and multiple sclerosis (Feinstein et al., 2002; Niino et al., 2001).es, College of Life Sciences &
iences, Foresterhill, Aberdeen,
license.These effects are primarily considered to be a result of the anti-
inﬂammatory actions of PPARγ. However, increases in anti-oxidant
gene expression (Nicolakakis et al., 2008) and modulation of choles-
terol metabolism (Xiong et al., 2008) are also thought to contribute
to the positive effects seen in Alzheimer's disease models. Indeed
PPARγ has been shown to be important for the regulation of a num-
ber of anti-oxidant genes including glutathione-S-transferases (Park
et al., 2004), Cu/Zn superoxide dismutase (SOD1) (Yoo et al., 1999)
and catalase (Girnun et al., 2002).
Parkinson's disease is a common neurodegenerative disease that
is characterised by loss of the dopaminergic neurons of the nigros-
triatal pathway (Dauer and Przedborski, 2003). The pathogenesis
of this disease is not fully understood, but is known to involve oxida-
tive stress, deriving in part from mitochondrial dysfunction and in-
ﬂammation (Hald and Lotharius, 2005). PPARγ agonists are
reported to attenuate inﬂammatory responses in mouse models of
PD, as measured by reductions in microgliosis and astrogliosis
(Dehmer et al., 2004; Breidert et al., 2002; Schintu et al., 2009;
Carta et al., 2011), and therefore the neuroprotective actions of
PPARγ agonists are primarily considered to result from their anti-
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that the protection of PPARγ agonists may also be due in part to
modulation of the oxidative stress response (Jung et al., 2007).
This study uses the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) model of PD to further explore the role of anti-oxidant
mechanisms in the neuroprotective actions of PPARγ agonists. It
also seeks to address whether these effects are mediated by PPARγ
as PPARγ agonists have been reported to have biological actions
which do not require the activation of PPARγ (Chintharlapalli et
al., 2005; Davies et al., 2001; Wang et al., 2011). MPTP is a neurotox-
in that can penetrate the blood brain barrier where it is converted by
monoamine oxidase-B in non-neuronal cells to its toxic metabolite
1-methyl-4-phenylpyridinium (MPP+) which is selectively taken
up by dopaminergic cells of the nigrostriatal pathway (Jackson-
Lewis and Przedborski, 2007). This toxin can be used in vitro in neu-
ronal cultures as MPP+ and in vivo as MPTP.
Experimental procedures
Chemicals
Rosiglitazone and GW9662 were from Alexis Biochemicals
(Exeter, UK). MPTP and MPP+ were from SigmaAldrich (Poole,
UK). All other chemicals unless otherwise stated were of analyti-
cal grade.
Cell culture
Human neuroblastoma SH-SY5Y cells were cultured in Dulbecco's
Modiﬁed Eagle Medium (DMEM; SigmaAldrich) supplemented with
10% foetal calf serum (Biosera, Ringmer, East Sussex, UK) and
100 units/ml penicillin/streptomycin/glutamine (Invitrogen, Paisley,
UK). Cells were kept at 37 °C in humidiﬁed 5% carbon dioxide and
95% air. Cells were seeded at 6000 cells/well in 96 well plates. All ex-
periments were carried out 48 h after seeding and in serum-free
media. Rosiglitazone and GW9662 were dissolved in dimethyl sulfox-
ide (DMSO) to make 1 mM solutions that were subsequently diluted
with Dulbecco's phosphate buffered saline (DPBS; SigmaAldrich)
and DMEM supplemented with 100 units/ml penicillin/streptomycin
for experimental use. Final solutions contained 0.1% DMSO (v/v).
MPP+ was dissolved in serum-free media and used at a ﬁnal concen-
tration of 1.5 μM. In experiments where rosiglitazone and GW9662
were used together with MPP+, cells were pre-treated with rosiglita-
zone or GW9662 for 16 h before the addition of MPP+. For co-
treatment experiments cells were pre-treated with GW9662 for
16 h to ensure a high level of PPARγ inactivation and to allow explo-
ration of the PPARγ dependence of the protective effects of
rosiglitazone.
Measurement of cell viability
Cell viability was determined by the conversion of the tetrazolium
salt, 3-(4,5-dimethylthizol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT; Invitrogen) to its insoluble formazan. After treatments 10 μl
of MTT solution (5 mg/ml) was added to the plated cells and incubat-
ed at 37 °C for 4 h. Media were then removed and the formazan solu-
bilised in 100 μl DMSO. The absorption of the resulting solution was
measured at 570 nm with reference at 670 nm using a PowerWave
XS microplate spectrophotometer (Bio-Tek, Potton, Bedfordshire,
UK).
Measurement of lactate dehydrogenase release
Release of lactate dehydrogenase (LDH) into the culture media
from cells with damaged membranes was measured using an assaykit (Cayman Chemicals, Ann Arbor, MI) as per manufacturer's
instructions.
Measurement of reactive oxygen species production
Reactive oxygen species (ROS) production was measured using
the conversion of 2′,7′-dichloroﬂuorescein diacetate (DCF-DA;
SigmaAldrich) to 2′,7′-dichloroﬂuorescein (DCF). Cells were plat-
ed and following treatments were rinsed with DPBS and incubat-
ed with 40 μM DCF-DA for 30 min at 37 °C. Cells were then rinsed
in DPBS and lysed overnight in the dark in 100 μl RIPA buffer
(50 mM Tris–HCl, pH 8; 150 mM NaCl; 1% NP-40; 0.5% sodium
deoxycholate; 0.1% SDS and protease inhibitors (cOmplete Mini
EDTA-free cocktail, Roche Diagnostics, Lewes, UK)) at 4 °C with
constant agitation. Fifty microlitres of lysate was then taken for
measurement of ROS production by comparison to a standard
curve of DCF with absorbance read at 500 nm. Twenty ﬁve micro-
litres of lysate was taken for a bicinchoninic acid (BCA) assay (as
per manufacturer's instructions (Pierce, Rockford, IL)) to allow
ROS production to be normalised to protein levels. One millimolar
L-buthionine-sulfoximine (BSO; SigmaAldrich) was used as a pos-
itive control.
Measurement of superoxide dismutase and glutathione-S-transferase
activity
Cells were plated in 25 cm2 ﬂasks and following treatments were
extracted in phosphate buffer (100 mM potassium phosphate, 2 mM
EDTA pH 7.0). Superoxide dismutase activity was then assayed
using an Epigentek (Brooklyn, NY) kit as per manufacturer's instruc-
tions. Glutathione-S-transferase activity was assessed using a Cayman
Chemicals kit as per manufacturer's instructions.
Animals and drug treatments
All mice were housed individually with a 12-hour/12-hour light/
dark cycle with free access to food and water. All procedures were
in accordance with the Animals (Scientiﬁc Procedures) Act 1986
and were approved by the Home Ofﬁce, Dundee, UK. MPTP handling
and safety measures were consistent with Jackson-Lewis and
Przedborski (2007). Twelve week-old male C57BL6 mice (Charles
River Laboratories, UK) (3–7 mice per timepoint) received intraperi-
toneal injections of MPTP-HCl (30 mg/kg free base — SigmaAldrich,
Poole, UK) dissolved in saline, one injection for ﬁve consecutive
days, and were killed at selected times ranging from 0 to 21 days
after the last injection. Control mice received saline only. For treat-
ment with PPARγ agonist or antagonist twelve week-old male
C57BL6 mice received intraperitoneal injections of 10 mg/kg rosigli-
tazone, 5 mg/kg of GW9662, or vehicle (5% DMSO v/v) daily for
3 days prior to MPTP administration, throughout MPTP administra-
tion (30 mg/kg for ﬁve consecutive days) and for 21 days following
MPTP administration. Mice were sacriﬁced 21 days after last MPTP
injection.
PPARγ, tyrosine hydroxylase (TH), glial ﬁbrillary acid protein (GFAP),
ionized calcium-binding adaptor molecule 1 (Iba1) and NeuN
immunohistochemistry
This was performed as described (Teismann et al., 2003) with the
minor modiﬁcation that incubation with primary antibodies was per-
formed sequentially as detailed below. Firstly incubation with either
rabbit anti-PPARγ (1:100; Alexis, San Diego, CA) or mouse anti-
PPARγ depending on host species of dual staining antibody, overnight
at 4 °C. Then 3×5 min washes in phosphate-buffered saline solution
(PBS) containing 0.1% Triton followed by incubation with mouse
anti-NeuN (1:100 Chemicon, Temecula, CA), mouse or rabbit anti-
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ﬁbrillary acidic protein (GFAP; 1:100; DAKO, Cambridgeshire, UK) or
rabbit anti-ionized calcium-binding adaptor molecule 1 (Iba1;
1:1000; Wako Chemicals, Neuss, Germany) overnight at 4 °C. Immu-
nostaining was visualised with Alexa Fluor 488 anti-rabbit or anti-
mouse (1:300; Molecular Probes, Eugene, OR) and cy-3 anti-rabbit
or anti-mouse (1:200; Jackson Immuno Research, West Grove, PA).
Immunostaining was visualised by confocal microscopy (LSM 510,
Carl Zeiss, Hertfordshire, UK).
RNA extraction and quantitative RT-PCR
Total RNA was extracted from selected brain regions using the
TRIzol (Invitrogen) homogenization method as in the manufacturer's
instructions. Samples were then subjected to a DNase digestion,
DNase I Amp Grade kit (Invitrogen), and ﬁrst strand cDNA synthesis
was carried out using the Superscript II kit (Invitrogen). The primer
sequences used in this study are detailed in Table 1. Quantitative
PCR ampliﬁcation was undertaken using the Lightcycler 480 and the
Lightcycler 480 SYBR green I Master (Roche Diagnostics, Lewes, UK)
as in the manufacturer's guidelines with annealing temperatures as
detailed in Table 1. The identity of fragments ampliﬁed with these
primers was conﬁrmed by DNA sequencing performed by The Se-
quencing Service (College of Life Sciences, University of Dundee, Scot-
land, www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1
chemistry on an Applied Biosystems model 3730 automated capillary
DNA sequencer.
Western blot analysis
Total proteins from mouse ventral midbrain, striatum and cer-
ebellum samples were isolated in NP-40 buffer (20 mM Tris–HCl
pH 8; 137 mM NaCl; 10% glycerol; 1% NP-40; 2 mM EDTA and
protease inhibitors (cOmplete Mini EDTA-free cocktail, Roche))
1:20 (wt/vol). Total proteins from human post-mortem ventral
midbrain, and striatum were isolated in NP-40 buffer 1:5 (wt/
vol). Protein concentration was determined using a BCA kit.
After boiling in Laemmli's buffer, 20 μg of protein was separated
by electrophoresis on a 10% sodium dodecyl sulphate–
polyacrylamide gel, transferred to nitrocellulose membrane, and
blocked with 5% non-fat dried milk in PBS containing 0.05%
Tween-20 (vol/vol) for 1 h. Incubation with rabbit anti-PPARγ
(1:1000; Alexis), rabbit anti-caspase 3 (1:2500; Abcam), rabbit
anti-superoxide dismutase 1 (1:1000; Assay Designs, Ann Arbor
MI) rabbit anti-glutathione-S-transferase π (1:1500; Assay De-
signs) or mouse anti-β-actin (1:25,000; SigmaAldrich) overnight
at 4 °C followed. Blots were then washed in PBS-Tween (0.05%)
and incubated with either an anti-rabbit (1:5000) or anti-
mouse (1:10,000) conjugated horseradish peroxidase antibody
(Amersham Biosciences, Buckinghamshire, UK) at room tempera-
ture for 1 h. Blots were then washed in PBS-Tween (0.05%) and
developed using a chemiluminescence solution (1 ml (50 mg
luminol sodium salt (SigmaAldrich) in 200 ml 0.1 M Tris–HCl pH
8.6), 100 μl (11 mg p-coumaric acid (SigmaAldrich) in 10 ml
DMSO) and 0.3 μl 30% hydrogen peroxide). Bands were visualisedTable 1
Primer sequences and annealing temperatures used for quantitative-PCR.
Target Forward primer (5′–3′)
Human SOD1 AAGGCCGTGTGCGTGCTGAA
Human GSTπ GCTCACTCAAAGCCTCCTGCCT
Human β-actin TGGTGGGCATGGGTCAGAAGGATT
Mouse PPARγ GAGCTGACCCAATGGTTGCTG
Mouse β-actin TGTGATGGTTGGGAATGGGTCAG
PPARγ — peroxisome proliferator-activated receptor γ; SOD1 — superoxide dismutase 1; Gwith an AlphaInnotech digital imaging system (San Leandro, CA)
and quantiﬁed with AlphaEase FC 5.02 software.
Stereological counting and analysis of striatal TH immunoreactivity
Immunostaining for stereological counting of TH and Nissl-
stained SNpc neurons was carried out on midbrain sections as
described in Teismann et al. (2003). Every 4th section was
taken until there were 12 sections for each substantia nigra
pars compacta (SNpc). The primary antibody was a polyclonal
rabbit anti-TH (1:1000; Chemicon) and staining was visualised
with 3,3′-diaminobenzidine (SigmaAldrich). The sections were
counted using light microscopy (AxioImager M1, Carl Zeiss) and
the optical fractionator method (West, 1993) (Stereo Investigator
version 7, MBF Bioscience, Magdeburg, Germany).
For analysis of striatal TH-immunoreactivity, every 8th section of
the striatum stained as described (Teismann et al., 2003) (rabbit
anti-TH (1:500; Chemicon)). TH immunoreactivity was assessed on
scans (Hewlett Packard Scanjet G3110, Bracknell, Berkshire, UK) of
the sections using Scion Image (Version 4.0.3.2 Scion Corporation,
MD).
HPLC analysis of striatal dopamine and 3,4-dihydroxyphenylacetic acid
(DOPAC) levels
High-performance liquid chromatography (HPLC) with electro-
chemical detection was used to measure striatal levels of dopamine,
and DOPAC using a method that has been described (Nuber et al.,
2008). Brieﬂy, mice were killed, 21 days after the last MPTP injection,
and the striata were dissected out and snap frozen on solid carbon di-
oxide. Striata were then homogenised in 0.1 M perchloric acid (1:30
wt/vol), sonicated and centrifuged at 18,600×g at 4 °C for 20 min.
Following centrifugation 20 μl of sample was injected onto a C18 col-
umn (Dionex, Germering, Germany). The mobile phase consisted of
90% 50 mM sodium acetate, 35 mM citric acid, 105 mg/l octane sul-
fonic acid, 48 mg/l sodium EDTA solution, and 10% methanol at pH
4.3. Flow rate was 1 ml/min. Peaks were detected by an ESA
Coulchem II electrochemical detector (ESA, Dionex), and the detector
potential was set at 700 mV. Data were collected and processed using
the Chromeleon computer system (Dionex).
Measurement of striatal MPP+ levels
Liquid chromatography with on-line ultraviolet detection/tan-
demmass spectrometry (LC-UV-MS-MS) was used to measure stria-
tal levels of MPP+. Brieﬂy, mice received drug treatment as outlined
in Animals and drug treatments section and 90 min after a single
MPTP injection (25 mg/kg) mice were sacriﬁced. The striata were
dissected out and snap frozen on solid carbon dioxide. Striata were
then sonicated in 0.1 M perchloric acid (1:30 wt/vol), and centri-
fuged at 14,000 rpm (18,620×g; Mikro 200R) at 4 °C for 20 min. Fol-
lowing centrifugation 2 μl of sample was injected onto a Hichrom 5μ
C18 column (Hichrom, Theale, UK). The mobile phase consisted of
80% 0.1% formic acid in water/20% 0.1% formic acid in acetonitrile.
Flow rate was 200 μl/min. MPP+ was detected by a photodiode
array detector set at 295 nm, and a triple quadrupole massReverse primer (5′–3′) Annealing temperature (°)
TGCCCAAGTCTCCAACATGCCT 64
AGTCATCCTTGCCCGCCTCA 64
AGGGATAGCACAGCCTGGATAGCA 64
GCTTCAATCGGATGGTTCTTC 62
TTTGATGTCACGCACGATTTCC 67
ST — glutathione-S-transferase.
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1.9 mTorr (ThermoSurveyor PDA/TSQ Quantum, ThermoScientiﬁc,
Loughborough, UK). Data were collected and processed using Xcali-
bur 2.0.7 SP1.
Statistical analysis
Data was analysed in SigmaPlot 11 for Windows (Systat Software
Inc., Chicago, IL). All values are expressed as the mean±SEM. Normal
distribution of the data was tested and the homogeneity of variance
conﬁrmed with Levene test. For single pairs of data Student t-tests
were used for comparisons between means. For data sets greater
than single pairs ANOVA was used to analyse differences among
means with time or treatment as the independent factor. When
ANOVA showed signiﬁcant differences post hoc testing was used to
make comparisons between means, Dunnett's post hoc test was
used for time-course studies and Student Newman–Keuls was used
to make pairwise comparisons in all other studies. Data not normally
distributed was analysed with the Kruskal–Wallis test followed by
Mann Whitney U-tests. The null hypothesis was rejected at the 0.05
level.
Results
Impacts of a PPARγ agonist and antagonist on MPP+-induced cytotoxic-
ity in vitro
Neither the PPARγ agonist rosiglitazone nor the antagonist
GW9662 alone had any impacts on cell viability as measured by as-
sessment of metabolic status by the reduction of MTT (Figs. 1A and
B). Cell viability was reduced by 56.5% by MPP+ treatment compared
to vehicle alone (pb0.001 ANOVA, Student Newman–Keuls post hoc
test; Fig. 1C). Next to assess the impact of rosiglitazone and/or
GW9662 on MPP+-induced cytotoxicity an initial pretreatment strat-
egy which then continued throughout MPP+ treatment was used.
This strategy was utilised as to accurately reﬂect the in vivo dosing re-
gime (see Animals and drug treatments and Effects of PPARγ
antagonist GW9662 on MPTP toxicity). This decrease was attenuated
by treatment with rosiglitazone at both 100 nM and 1 μM although
only the latter reached statistical signiﬁcance (p=0.078 100 nM;
pb0.05 1 μM ANOVA, Student Newman–Keuls post hoc test). Treat-
ment with GW9662 at 1 μM did not impact on MPP+-induced toxici-
ty. However co-treatment with rosiglitazone (1 μM) and GW9662
(1 μM) (see Cell culture section for details) prevented the protective
effect of rosiglitazone alone (pb0.01 ANOVA, Student Newman–
Keuls post hoc test) suggesting not simply a PPARγ independent
mechanism, but rather having an additive or potentiating toxic effect.
A second measure of cell viability that does not involve metabolic
status, the LDH assay which assesses membrane integrity, was used
as PPARγ has many roles in cell metabolism (Desvergne and Wahli,
1999). In this assay MPP+ increased LDH activity (pb0.001 ANOVA,
Student Newman–Keuls post hoc test; Fig. 1D) and again this was at-
tenuated by rosiglitazone treatment (pb0.01 ANOVA, Student New-
man–Keuls post hoc test) and unaffected by GW9662 treatment. In
contrast to the cell viability assay co-treatment did not prevent the
protective effect of rosiglitazone, suggesting that the impacts of rosi-
glitazone on this measure of cytotoxicity do not require PPARγ-
activation.
Impacts of a PPARγ agonist and antagonist on MPP+-induced oxidative
stress in vitro
To further explore the protective mechanisms of rosiglitazone and
the PPARγ dependence of these effects the generation of reactive ox-
ygen species (ROS) was assessed. L-Buthionine-sulfoximine (BSO)
was used as a positive control to ensure ROS generation wasdetectable and after 24 h of treatment with 1 mM BSO ROS levels
were 1.45-fold higher than those of the control (pb0.01 Kruskal–
Wallis test, Mann Whitney-U post hoc test). Twenty-four hours of
MPP+ treatment induced ROS levels over 2-fold higher than those
in control cells (pb0.01 Kruskal–Wallis test, Mann Whitney-U post
hoc test; Fig. 2A). This increase was attenuated by the rosiglitazone
treatment (pb0.05 Kruskal–Wallis test, Mann Whitney-U post hoc
test) back to the level of control cells. GW9662 did not affect MPP+-
induced ROS formation. Co-treatment with GW9662 did not affect
the protective effects of rosiglitazone treatment suggesting that the
protective effect of rosiglitazone does not require PPARγ activation
(pb0.05 Co-treatment vs. MPP+ alone Kruskal–Wallis test, Mann
Whitney-U post hoc test).
These data suggest that treatment with rosiglitazone attenuates
MPP+-induced ROS formation without PPARγ activation, to conﬁrm
this the role of two anti-oxidant genes implicated in MPTP toxicity
and known to be PPARγ responsive – Cu/Zn superoxide dismutase
(SOD1) (Yoo et al., 1999; Fornai et al., 2002) and GSTπ (Park et al.,
2004; Smeyne et al., 2007) was investigated 24 h after MPP+ treat-
ment. This timepoint was chosen as ROS formation was signiﬁcantly
increased, but alterations in caspase 3 levels indicative of cell death
were not detected (Fig. 2B). Only treatment with GW9662 increased
SOD1 mRNA levels when compared to MPP+ treated cells (pb0.05
ANOVA, Student Newman–Keuls post hoc test; Fig. 2C). This did not
correlate to an increase in SOD1 protein levels (Fig. 2D). The lack of
effect of rosiglitazone on SOD1 was further conﬁrmed as no alter-
ations in SOD activity (Cu/Zn and Mn SOD activity were assessed to-
gether) were seen when compared to control cells 24 h after MPP+
administration (Fig. 2E). Expression of GSTπ mRNA was increased
with GW9662 and co-treatment (GW9662 vs. MPP+ pb0.01; co-
treatment vs. MPP+ pb0.05 ANOVA, Student Newman–Keuls post
hoc test; Fig. 2F). Similar to SOD1 these increases were not reﬂected
at the protein level (Fig. 2G). However alterations in global GST activ-
ity (all GST isoforms, including GSTπ) were detected (Fig. 2H), treat-
ment with MPP+ demonstrated a trend towards reduced GST activity
(p=0.073 compared to control cells Kruskal–Wallis test, Mann
Whitney-U post hoc test). This decrease was attenuated by both rosi-
glitazone and co-treatment (pb0.05 rosiglitazone vs. vehicle; pb0.05
co-treatment vs. vehicle; Kruskal–Wallis test, Mann Whitney-U post
hoc test) and unaffected by treatment with GW9662, supporting the
independence of these effects from PPARγ activation.
Effects of MPTP treatment on PPARγ levels in vivo
As demonstrated in vitro the PPARγ agonist rosiglitazone has anti-
oxidant effects that appear not to require PPARγ activation, and
which may contribute to the previously documented neuroprotective
effects of rosiglitazone in in vivo models of PD (Schintu et al., 2009;
Carta et al., 2011). In order to determine if the in vitro anti-oxidant ef-
fects of rosiglitazone could be translated to an in vivo model of PD,
ﬁrst any alterations in PPARγ levels in the substantia nigra pars com-
pacta (SNpc), the main area of neuron loss in PD, were examined by
western blot and qPCR analysis. Quantitative PCR showed a signiﬁ-
cant increase in PPARγ mRNA levels in the ventral midbrain (the
area containing the SNpc) 7 days after MPTP administration com-
pared to saline-treated mice (pb0.01 ANOVA, Student Newman–
Keuls post hoc test; Fig. 3A) when normalised to β-actin levels (β-
actin levels were unchanged by MPTP treatment, data not shown).
This increase correlated with a rise in PPARγ protein levels
(pb0.001 ANOVA, Student Newman–Keuls post hoc test; Fig. 3B).
No alterations in PPARγ protein levels were seen in either the stria-
tum (Fig. 3C) or the cerebellum (Fig. 3D).
Subsequently the cellular localisation of PPARγ in the SNpc was
ascertained in both saline- and MPTP-treated mice to determine if a
particular cell type was responsible for the upregulation in PPARγ
levels seen after MPTP treatment. PPARγ is expressed in a peri-
Fig. 1. Effects of the PPARγ agonist, rosiglitazone and the antagonist, GW9662 on MPP+ cytotoxicity as measured by cell viability and lactate dehydrogenase (LDH) release. The
impact of rosiglitazone (A) and GW9662 (B) on cell viability was assessed by MTT reduction, no alterations in cell viability were seen. After 48 h MPP+ (1.5 mM) decreased cell
viability in vehicle (0.1% DMSO) treated cells, this was attenuated by rosiglitazone (1 μM) (C). Co-treatment with GW9662 (1 μM) prevented the protective effects of rosiglitazone.
LDH release was increased after MPP+ treatment (1.5 mM) and again this was attenuated by rosiglitazone (1 μM) (D). However, GW9662 (1 μM) did not prevent the protective
effects of rosiglitazone in this assay. Data are mean±SEM, n=3, ###pb0.001 MPP+ compared to control; *pb0.05; **pb0.01 compared to MPP+ with vehicle, ††pb0.01 co-
treatment compared to rosiglitazone treatment (ANOVA followed by Student Newman–Keuls post hoc test).
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in the SNpc (Fig. 4A i–iii, and Fig. 4B i–iii, iv–vi and vii) in both saline-
and MPTP-treated mice. No expression of PPARγ was detected in as-
trocytes of either saline or MPTP treated mice, nor microglia of saline
treated mice (Fig. 4A iv–vi, vii–ix and Fig. 4B vii–x). However, PPARγ
expression was detected in amoeboid microglial cells 7 days after
MPTP treatment (Fig. 4B xi–xii), suggesting that this cell type maybe the cell type responsible for the upregulation of PPARγ levels
seen with MPTP treatment.
Effects of PPARγ antagonist GW9662 on MPTP toxicity
The protective effect of rosiglitazone and other glitazones against
MPTP toxicity has been reported elsewhere (Schintu et al., 2009;
Fig. 2. Effects of the PPARγ agonist, rosiglitazone and the antagonist, GW9662 on MPP+-induced reactive oxygen species (ROS) formation and alterations in the expression of caspase 3
and anti-oxidant enzymes. ROS formation was assessed by conversion of DCF-DA to DCF. After 24 h both MPP+ (1.5 mM) and L-buthionine-sulfoximine (1 mM, BSO) had induced ROS
formation (A). Rosiglitazone (1 μM) attenuated the MPP+-induced ROS formation and this protective effect was unaltered by co-treatment with GW9662 (1 μM). Levels of activated
caspase 3 protein were assessed 24 h after MPP+ treatment and shown no change (B). Levels of superoxide dismutase and glutathione-S-transferase-π (GSTπ) mRNA and protein
after treatment with MPP+, rosiglitazone, GW9662 or co-treatment of rosiglitazone and GW9662 were evaluated. Only treatment with GW9662 increased SOD1 and GSTπ mRNA
(C and F), and these changes did not correlate with changes in protein levels (D and G). No alteration in SOD activity was seen (E). MPP+ reduced GST activity non-signiﬁcantly and
this reduction was attenuated by both rosiglitazone and co-treatment (H). Data are mean±SEM, n=3, ##pb0.01 MPP+ compared to control; *pb0.05; **pb0.01 compared to
MPP+ alone, ††pb0.01 co-treatment compared to rosiglitazone treatment (ANOVA followed by Student Newman–Keuls post hoc test; Kruskal–Wallis test followed by Mann
Whitney-U post hoc test) for ROS formation and GST activity; ROS — reactive oxygen species; SOD1 — superoxide dismutase 1; GST — Glutathione-S-transferase.
533H.L. Martin et al. / Experimental Neurology 235 (2012) 528–538Dehmer et al., 2004; Breidert et al., 2002). To permit the work of this
study to be comparable with these studies a pretreatment strategy as
outlined in Animals and drug treatments section was adopted. How-
ever, in this study rosiglitazone signiﬁcantly reduced striatal MPP+levels when compared to vehicle (5% DMSO) (pb0.05 Kruskal–Wallis
test, Mann Whitney U post hoc test; Table 2) thus indicating that it
was interfering with MPTP bioactivation preventing its use in this
MPTP model as it would not be possible to deﬁnitively attribute any
Fig. 3. Alterations in PPARγ expression following MPTP treatment. PPARγmRNA levels in the ventral midbrain are increased seven days after MPTP compared to saline treated mice
(A), and this corresponds to an increase in PPARγ protein levels (B). PPARγ protein levels are unchanged in the striatum (C) and cerebellum (D). Data are mean±SEM, n=3–6
mice per timepoint. **pb0.01, ***pb0.001 compared to saline (ANOVA with student Newman–Keuls post hoc test) (d — days after MPTP (5×30 mg/kg daily) administration).
Fig. 4. PPARγ immunolocalisation in saline and MPTP treated mice. Double immunoﬂuorescence conﬁrms that PPARγ (green) is expressed in neuronal nuclei in the substantia nigra
pars compacta with NeuN (A and B i–iii; red), including in TH-positive neurons (A and B iv–vi and vii; red), in both saline and MPTP treated mice. PPARγ did not colocalise with
GFAP-positive astrocytes (A and B viii–x; red) in either saline or MPTP treated mice. Colocalisation of PPARγwith Iba1-positive microglia was seen seven days after MPTP treatment
(B xi–xiii; red). (Scale bars are 20 μm).
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Table 2
Effect of rosiglitazone and GW9662 on striatal levels of MPP+. Rosiglitazone reduced
striatal MPP+ levels compared to mice receiving vehicle (5% DMSO v/v). No differences
were seen in striatal levels of MPP+ between mice infused with GW9662 or those re-
ceiving vehicle. Data are mean±SEM, n=4 mice per group. *pb0.05 compared to ve-
hicle treated group (Kruskal–Wallis test with Mann Whitney U-post hoc tests).
Vehicle Rosiglitazone GW0742
MPP+ (μg/g wet tissue weight) 12.31±2.90 3.42±0.70* 11.66±3.46
535H.L. Martin et al. / Experimental Neurology 235 (2012) 528–538protective effects seen to rosiglitazone itself. Subsequently it was nec-
essary to address the role of PPARγ in dopaminergic neuron death fol-
lowing MPTP treatment using an inhibitory approach. PPARγ
inhibition was tested by the administration of the PPARγ antagonist
GW9662 as PPARγ knock-out mice are embryonically lethal (Barak
et al., 1999) and conditional knock-out mice were unavailable.
MPTP treatment reduced both TH- and Nissl-positive neurons in the
SNpc compared to saline-treated mice in both treatment groups (TH
6065±485 vs. 2948±128, pb0.001 for vehicle and 4030±759 vs.
2295±395, pb0.05 for GW9662 treatment; Nissl 12960±698 vs.
8056±319, pb0.0001 for vehicle and 9150±514 vs. 5725±373,
pb0.01 for GW9662 treatment). GW9662 alone reduced TH and
Nissl neuron numbers in saline-treated mice (pb0.01 TH and
pb0.001 Nissl ANOVA, Student Newman–Keuls post hoc test; Figs.
5A–C). In combination with MPTP only Nissl neuron numbers were
further reduced by GW9662 treatment compared to MPTP and vehi-
cle (p=0.006 ANOVA, Student Newman–Keuls post hoc test).
The effect of GW9662 on MPTP-induced striatal damage was eval-
uated by measuring TH immunoreactivity and HPLC measurement of
the levels of dopamine and its metabolite DOPAC. MPTP induced aFig. 5. Effects of GW9662 treatment on MPTP neurotoxicity. GW9662 treatment alters neuro
micrographs. Both TH-positive neuron (B) and Nissl neuron (C) numbers were reduced by G
MPTP (5×30 mg/kg daily i.p.) reduced TH-positive and Nissl-positive neuron number. GW9
ences were detected in striatal TH-immunoreactivity (D and E) between mice treated wit
*pb0.05; **pb0.01; ***pb0.001 (ANOVA with Student Newman–Keuls post hoc test).reduction in striatal TH immunoreactivity in both vehicle- and
GW9662-treated mice (pb0.001 for both groups ANOVA, Student
Newman–Keuls post hoc test; Figs. 5D and E). This reduction was
not affected by GW9662 treatment, however, GW9662 did show a
trend towards reduction of striatal TH immunoreactivity in saline-
treated mice (p=0.052 ANOVA, Student Newman–Keuls post hoc
test). MPTP administration induced signiﬁcant reductions in the
levels of dopamine and DOPAC in the striatum detected by HPLC in
both groups (Dopamine pb0.05 vehicle and pb0.001 GW9662;
DOPAC pb0.01 vehicle and pb0.001 GW9662 Kruskal–Wallis test,
Mann Whitney U post hoc test; Table 3). GW9662 treatment did not
affect dopamine and DOPAC levels in saline-treated mice.Discussion
PPARγ agonists have been shown to be neuroprotective in a num-
ber of neurodegenerative diseases (Escribano et al., 2009; Kiaei et al.,
2005; Feinstein et al., 2002; Niino et al., 2001) including PD (Dehmer
et al., 2004; Breidert et al., 2002; Schintu et al., 2009; Carta et al.,
2011). These effects are predominantly considered to result from
the anti-inﬂammatory actions mediated by PPARγ activation
(Dehmer et al., 2004; Schintu et al., 2009; Kiaei et al., 2005), indeed
both rosiglitazone and pioglitazone have been shown to reduce
microgliosis and astrogliosis in the MPTP mouse model of PD
(Dehmer et al., 2004; Breidert et al., 2002; Schintu et al., 2009).
There is also growing evidence that PPARγ agonists have anti-
oxidant effects (Nicolakakis et al., 2008; Xiong et al., 2008; Jung et
al., 2007) and PD pathogenesis also involves oxidative stress
(Jenner, 2003). In this study administration of rosiglitazone attenuat-
ed MPP+-induced alterations in SH-SY5Y cell viability which was co-
incident with a reduction in MPP+-induced ROS production. The usenal sensitivity to MPTP toxicity. (A) Representative micrographs of TH and Nissl stained
W9662 treatment in saline-treated mice compared to vehicle treated mice (5% DMSO).
662 treatment enhanced the impact of MPTP on Nissl-positive neurons only. No differ-
h GW9662 and vehicle treated mice. Data are mean±SEM, n=4–5 mice per group.
Table 3
Effect of GW9662 treatment on striatal dopamine and DOPAC levels. No difference is
seen in MPTP induced reductions in dopamine and DOPAC levels between mice treated
with GW9662 (5 mg/kg daily) or those receiving vehicle (5% DMSO — see text for de-
tails). Data are mean±SEM, n=4–5 mice per group. *pb0.05, **pb0.01, ***pb0.001
compared to appropriate saline treated group (Kruskal–Wallis test with MannWhitney
U-post hoc tests).
Saline MPTP
Vehicle GW9662 Vehicle GW9662
Dopamine (ng/mg wet
tissue)
11.81±1.80 14.01±1.40 1.13±0.30* 1.00±0.45***
DOPAC (ng/mg wet
tissue)
1.62±0.38 1.41±0.22 0.25±0.10** 0.22±0.04***
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require PPARγ activation as in the majority of experiments in this
study co-treatment did not attenuate the protective effects of rosigli-
tazone. The exception to this was the MTT assay measuring cell viabil-
ity, where co-treatment with GW9662 and rosiglitazone did
attenuate the protective effects of rosiglitazone alone, suggesting
that the observed effect is due to an additive or potentiating toxic ef-
fect of the compounds. The independence of the effects seen on ROS
formation from PPARγ activation is supported by the lack of change
in the activity of SOD in vitro, as SOD1 is a key anti-oxidant enzyme
with a known peroxisome proliferator response element (PPRE)
(Yoo et al., 1999) and would be expected to change if the effects of
rosiglitazone were PPARγ dependent. This lack of change in SOD ac-
tivity is in contrast to previous work (Jung et al., 2007), but a different
dose regime and timepoint were examined in that study. As the initial
impact of rosiglitazone on oxidative stress was not mediated by in-
creased SOD activity, it may have arisen from changes in GST activity
as GSTs are important for detoxiﬁcation of a number of oxidative
stress products such as peroxidated polyunsaturated fatty acids and
4-hydroxy-2-alkenals (Hayes et al., 2005). Rosiglitazone did attenu-
ate the MPP+-induced reduction in GST activity suggesting that mod-
ulation of GST activity is involved in the early anti-oxidant effects of
rosiglitazone. Co-treatment of rosiglitazone and GW9662 also had a
positive effect on GST activity suggesting that this protective effect
of rosiglitazone may also not require PPARγ activation. PPARγ ago-
nists have been documented to have actions that do not require
PPARγ activation in previous studies (Chintharlapalli et al., 2005;
Davies et al., 2001; Wang et al., 2011), including in a model of brain
trauma where pioglitazone reduced the inﬂammatory response in a
manner unaltered by the administration of the PPARγ antagonist
T0070907 (Thal et al., 2011).
The in vitro work of this study shows rosiglitazone to have
anti-oxidant effects that do not require PPARγ activation, and
previous studies have shown rosiglitazone to have protective
effects in vivo (Schintu et al., 2009; Carta et al., 2011) which
may involve anti-oxidant effects in addition to the documented
attenuation of microglial and astrocytic activation. Subsequently
it was important to determine the relevance of our ﬁndings to
the in vivo situation using the MPTP model of PD. PPARγ was
expressed in the neurons of the SNpc correlating with previous
work (Carta et al., 2011; Ou et al., 2006). PPARγ has also been
documented to be expressed in microglia (Carta et al., 2011;
Bernardo et al., 2000; Storer et al., 2005), and this was the
case in MPTP-treated mice in this study, however, only Iba1-
positive microglia of an amoeboid phenotype were positive
for PPARγ. This is also consistent with Carta et al. (2011)
who have shown that PPARγ co-localisation with a microglial
marker, CD11b, is increased by MPTP treatment. As PPARγ
levels were not upregulated until seven days after MPTPtreatment it is unlikely that the PPARγ expression that occurs
in activated microglia plays a signiﬁcant role in MPTP toxicity,
as the majority of dopaminergic neuron loss has occurred by
this timepoint (Jackson-Lewis et al., 1995). However, the pres-
ence of PPARγ in activated microglia may underlie some of
the positive effects of PPARγ agonists as these pharmacological
interventions increase the negative regulatory effects of PPARγ
on inﬂammation (Jiang et al., 1998; Ricote et al., 1998) and
the reduction of microglia inﬂammatory responses has been
shown to attenuate MPTP toxicity (Wu et al., 2002). The strong
presence of PPARγ in neurons suggests that modulation of in-
ﬂammatory responses may not be the whole picture.
Further investigations of the protective effects of rosiglita-
zone against MPTP were indicated however, rosiglitazone treat-
ment was found to interfere with the metabolic activation of
MPTP. This is in contrast to the work of Schintu et al. (2009)
who did not see alterations in MPTP bioactivation following
rosiglitazone treatment. However, the use of a clearance inhib-
itor, probenecid, and differences in the methodology used for
measurement of MPP+ level means deﬁnitive comparisons be-
tween this study and that of Schintu et al. (2009) are not pos-
sible. Another glitazone, pioglitazone, has been shown to
interfere with the activation of MPTP by inhibiting monoamine
oxidase B (MAO-B), which converts MPTP to its active metabo-
lite MPP+ (Quinn et al., 2008) suggesting that the glitazones as
a drug class may be neuroprotective in the MPTP mouse model
by a mechanism that is irrelevant to PD pathogenesis.
Consequently these data meant an inhibitory approach was
necessary to address the role of PPARγ in the MPTP model of
PD. Ideally a PPARγ null mouse would have been utilised, how-
ever, PPARγ null mice are not viable (Barak et al., 1999) and
conditional PPARγ null mice were unavailable. Subsequently
administration of GW9662, an irreversible PPARγ antagonist,
was used. GW9662 was toxic to neurons, including dopaminer-
gic neurons, in the SNpc of both saline and MPTP treated mice.
As this study focussed on the brain regions affected in PD,
namely the SNpc and the striatum, no other brain regions
were assessed. It would, however, be interesting to further ex-
plore if treatment with GW9662 and subsequently PPARγ an-
tagonism has global neurotoxicity as suggested by studies in
other neurodegenerative diseases including Huntington's dis-
ease (Quintanilla et al., 2008) and Alzheimer's disease (Du et
al., 2009).
Other PPARγ antagonists are implicated in neurotoxicity,
bisphenol A diglycidyl ether (BADGE) worsens clinical scores
in the experimental allergic encephalomyelitis model of multi-
ple sclerosis (Raikwar et al., 2005). Taken together these data
suggest that PPARγ activity is important for neuronal survival
especially under conditions of cellular stress and this idea is
further supported by increased susceptibility to cerebral ische-
mia in mice with a neuronal deﬁciency of PPARγ (Zhao et al.,
2009). Further work is required to determine if the toxic im-
pacts of GW9662 seen in the study require the presence of
PPARγ. The mechanism of toxicity also needs further elucida-
tion, to identify the novel pathway involved and whether
these effects do not require PPARγ to be present or to ascertain
which pathways involving PPARγ are important for these ef-
fects. One possible mechanism is a reduction of mitochondrial
membrane potential (Quintanilla et al., 2008) which can lead
to mitochondrial dysfunction, opening of mitochondrial perme-
ability transition pores, cytochrome c release and apoptosis
(Zorov et al., 2009). To this end PPARγ activation has been
shown to upregulate Bcl-2 (Fuenzalida et al., 2007), an anti-
apoptotic protein which inhibits the opening of mitochondrial
permeability transition pores (Zorov et al., 2009). Alternatively
inhibition of PPARγ may promote or exacerbate a harmful pro-
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anti-inﬂammatory response (Delerive et al., 2001; Desvergne
and Wahli, 1999; Devchand et al., 1996). It will be interesting
to see which mechanisms are involved but, given the complex-
ity of PPARγ functions, it is likely to be a combination of many
different pathways.
In conclusion, there is growing evidence that some of the cel-
lular protective effects of PPARγ agonists do not require the acti-
vation of PPARγ (Chintharlapalli et al., 2005; Davies et al., 2001;
Wang et al., 2011; Thal et al., 2011). The current study has ex-
tended these ﬁndings to the MPTP/MPP+ model of PD and sug-
gests that prevention of oxidative stress is an important
mechanism underlying the protective effect of rosiglitazone, but
one that is independent of PPARγ activation. However, further
studies using genetic manipulation strategies are needed to con-
ﬁrm these effects are independent of PPARγ activation. It also
suggests that the glitazones as a drug class may impact upon
the conversion of MPTP to its active metabolite MPP+ and that
the protective effects attributed to this drug class may need care-
ful reassessment. It is also worth noting that rosiglitazone has
been removed from the European market as an antidiabetic due
to cardiovascular toxicity and pioglitazone due to increasing the
risk of bladder cancer (EMA/CHMP/586211/2010), affecting their
consideration as useful translational drugs for the treatment of
PD. This study has also demonstrated that PPARγ is important
for neuronal survival as GW9662 was toxic to neurons. The re-
sults of this study add weight to there being a protective role
for PPARγ agonists against MPTP toxicity, but also highlight the
need for caution when manipulating PPARγ by pharmacological
means.
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